Adaptive Radiation Therapy for Cancer
Trial Summary
What is the purpose of this trial?
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment involving 18F-fluoromisonidazole (FMISO) and imaging techniques like MRI and PET scans for cancer?
Research shows that 18F-fluoromisonidazole (FMISO) is effective in identifying hypoxic (low oxygen) areas in tumors, which are often more resistant to radiation therapy. This imaging helps doctors better target these areas during treatment, potentially improving the effectiveness of radiotherapy for cancer.12345
Is MRI safe for use in humans?
How is adaptive radiation therapy different from other cancer treatments?
Adaptive radiation therapy is unique because it uses real-time MRI guidance to adjust the treatment plan during the course of therapy, allowing for more precise targeting of the tumor while minimizing radiation exposure to surrounding healthy tissues. This approach provides superior soft-tissue contrast and enables personalized treatment adjustments based on anatomical and biological changes, which is not possible with traditional X-ray-based radiotherapy.1112131415
Research Team
Evan Osmundson, MD
Principal Investigator
Vanderbilt University/Ingram Cancer Center
Eligibility Criteria
This trial is for adults with certain head and neck cancers or brain tumors, who can be measured by scans, have a life expectancy over 6 months, and are in good physical condition. They must not be pregnant, agree to use birth control, and able to consent.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-Treatment Assessment
Participants undergo MRI and PET scans to assess tumor hypoxia using 18F-fluoromisonidazole
Treatment
Participants receive standard of care stereotactic radiosurgery guided by MRI-based markers of tumor hypoxia
Follow-up
Participants are monitored for tumor recurrence, progression, and radiation necrosis post-treatment
Long-term Follow-up
Participants are evaluated for long-term effects of treatment on tumor hypoxia and radiation necrosis
Treatment Details
Interventions
- 18F-fluoromisonidazole
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt-Ingram Cancer Center
Lead Sponsor
National Institutes of Health (NIH)
Collaborator